Summary Glycoprotein 41 (gp41) - Gp41 or glycoprotein 41 is a transmembrane protein that contains several sites within its ectodomain that are required for infection of host cells. It is a subunit of the envelope protein complex of retroviruses. The interaction of gp41 fusion peptides with the target cell causes a formation of an intermediate structure which bridges and fuses the viral and host membranes together.
Glycoprotein 41 (gp41) pipeline Target constitutes close to 18 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 1, 5 and 1 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 1 and 5 molecules, respectively. Report covers products from therapy areas Infectious Disease which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS).
The latest report Glycoprotein 41 - Pipeline Review, H2 2020, outlays comprehensive information on the Glycoprotein 41 (gp41) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The report provides a snapshot of the global therapeutic landscape for Glycoprotein 41 (gp41)
- The report reviews Glycoprotein 41 (gp41) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glycoprotein 41 (gp41) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glycoprotein 41 (gp41) targeted therapeutics
Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glycoprotein 41 (gp41)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glycoprotein 41 (gp41) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Our reports have been used by over 10K customers, including:
The global immunofluorescence assays market is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6.0% during the forecast period. The growth in this market is primarily attributed to the increasing prevalence of chronic diseases and rising R&D spending & healthcare expenditure. Emerging markets are expected...
200 pages •
By The Business Research Company
• Dec 2020
Major players in the anatomical pathology equipment and consumables market are Epridea, F. Hoffmann-La Roche Ltd., Danaher Corporation, Thermo Fisher Scientific, Sakura Finetek, Agilent Technologies, Danaher Corporation, Bio SB, BioGenex Laboratories, and Quest Diagnostics Incorporated. The global anatomic pathology equipment and consumables...
Anatomic Pathology Market Report Overview Anatomic Pathology market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Anatomic Pathology market types and applications. It is a focused study on Anatomic Pathology market space including global...
Pathology Devices Market Report Overview Pathology Devices market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Pathology Devices market types and applications. It is a focused study on Pathology Devices market space including global and...
200 pages •
By The Business Research Company
• Mar 2021
Major players in the ultra-low temperature freezers market are Arctiko, Eppendorf, Esco Micro Pte Ltd, Haier, Helmer Scientific, Bionics Scientific Technologies (P). Ltd, PHC Holdings Corporation, Labcold Ltd, Remi Group, and Stirling Ultracold. The global ultra-low temperature freezers market is expected to decline from $633.94 million...
Digital Pathology Market Size, Share & Trends Analysis Report By Product (Software, Device), By Application (Drug Discovery & Development, Academic Research), By End-use, By Region, And Segment Forecasts, 2021 - 2028 Digital Pathology Market Growth & Trends The global digital pathology market...
The global organoids market is expected to reach US$ 3,420.40 million by 2027 from US$ 689.47 million in 2019. The market is estimated to grow at a CAGR of 22.1% from 2020 to 2027. Increasing demand for tumor modelling and biobanking, rising adoption of personalized drugs, and growing focus on developing alternatives for animal testing...
The current practice of medical education and methods of performing surgery and therapy suffer from limitations such as scarcity of subjects to practice on, suboptimal surgical precision, and therapy-related issues including medication misuse and ineffectiveness of the drugs to treat the conditions. Moreover, the outbreak of COVID-19 pandemic...
An organ-on-a-chip is a microfluidic cell culture device that contains continuously perfused chambers. This chip develops a narrow channel for the blood and airflow in organs, such as the lung, gut, liver, heart, and other organs. Such devices produce multiple levels of tissue and organ functionalities, which are not feasible using conventional...
KEY FINDINGS The global disposable patient positioning products market is anticipated to register a CAGR of 3.21%, during the forecast years of 2021 to 2028. The primary market growth drivers include the growing volume of surgeries, the rise in the geriatric population, and the surging investments across the healthcare...
Surgical Procedures Performed
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.